NeoGenomics Q1 revenue rises, driven by NGS segment growth

NeoGenomics

28/04/2026 21:30

driven by Clinical
Overview

US cancer diagnostics firm's Q1 revenue rose 11% yr/yr, beating analyst expectations

Adjusted net income turned positive in Q1, while net loss narrowed by 34%

Company raised full-year 2026 revenue guidance, citing new product launches and coverage gains

Outlook

NeoGenomics raises full-year 2026 revenue guidance to $797 mln-$803 mln

Company maintains full-year 2026 net loss forecast of $63 mln-$50 mln

NeoGenomics expects full-year 2026 adjusted EBITDA of $55 mln-$57 mln

Result Drivers

CLINICAL REVENUE GROWTH - Co said 14% growth in clinical revenue, including 26% growth in NGS, drove overall revenue increase

NEW PRODUCT LAUNCHES - Co cited the launch of RaDaR ST MRD assay and PanTracer Pro as expanding its advanced cancer testing portfolio

REIMBURSEMENT COVERAGE - Co pointed to favorable MolDX coverage decision for PanTracer LBx as supporting test adoption

Company press release: ID:nBw3WWHS5a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$187 mln
$184.51 mln (13 Analysts)
Q1 Adjusted Net Income
$1.40 mln
Q1 Net Income
-$17 mln
Q1 Adjusted EBITDA
$9 mln
Q1 Gross Profit
$81 mln
Q1 Operating Expenses
$99.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $15.00, about 74.2% above its April 27 closing price of $8.61

The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 73 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)